NCT04195633
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, +59 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Refractory Marginal Zone Lymphoma
Explore clinical trials studying Refractory Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.
13 public trials
2 recruiting studies
Refractory Marginal Zone Lymphoma trial results
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Chronic Disease, Disease Attributes, +35 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
NCT03277729
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, not recruiting
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
Active, not recruiting
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
Active, not recruiting
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT05025800
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, not recruiting
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
NCT04447716
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States
NCT04205409
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +46 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT02568553
- Conditions
- Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
Completed
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
NCT01995669
- Conditions
- Chronic Disease, Disease Attributes, Grade 3a Follicular Lymphoma, +28 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States